Related Experiment Video
Updated: Aug 6, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Identification of human T-cell epitopes and highly immunogenic analog peptides on the non-typeable Haemophilus
Yoshiya Ishida1, Yusuke Abe, Mitsuru Yanai
1Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical College, Midorigaoka E2-1-1-1, Asahikawa, Hokkaido 078-8510, Japan.
Insights
New peptide analogs targeting non-typeable Haemophilus influenzae (NTHi) show promise for a vaccine. These enhanced peptides may improve immune responses in children prone to recurrent ear infections.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Non-typeable Haemophilus influenzae (NTHi) causes acute otitis media, particularly in children.
- The P6 outer membrane protein is a potential vaccine candidate, but responses are inadequate in otitis-prone children.
- Novel vaccination strategies are needed to enhance immune responses against NTHi.
Purpose of the Study:
- To develop an effective peptide vaccine against NTHi infections.
- To identify and optimize T-cell epitopes on the P6 protein for improved immunogenicity.
Main Methods:
- Established P6-specific CD4(+) T-cell lines (TCLs) restricted by HLA-DR9.
- Identified a core T-cell epitope (p77-85; EYNIALGQR) on the P6 protein.
- Synthesized and tested three analog peptides (E77D, N79G, R85K) for their immunogenic potential.
Main Results:
- The identified T-cell epitope (p77-85) was characterized.
- Analog peptides E77D, N79G, and R85K demonstrated significantly higher proliferative responses and cytokine production compared to the original epitope.
- These analogs represent potentially more effective vaccine components.
Conclusions:
- The P6-derived analog peptides show potential as candidates for a peptide vaccine against NTHi.
- These analogs may overcome the inadequate immune responses observed with P6 alone, especially in otitis-prone children.
- Further development of these analogs could lead to improved NTHi vaccines.
Abstract:
P6 outer membrane protein is one of the candidates for a vaccine formulation against non-typeable Haemophilus influenzae (NTHi) infection. However, otitis-prone children who have recurrent episodes of acute otitis media due to NTHi fail to respond adequately to P6. An innovative approach to vaccination is therefore required to augment such children's immune response. To develop an effective peptide vaccine, we established P6-specific CD4(+) T-cell lines (TCLs) restricted by the human histocompatibility leukocyte antigen (HLA)-DR9 molecule, and revealed a human T-cell epitope on P6 and its core peptide sequence (p77-85; EYNIALGQR). Furthermore, we found that 3 analog peptides, E77D (the substitution of E at position 77 with D), N79G, and R85K, induced high proliferative responses as well as marked cytokine production when compared to the T-cell epitope peptide. These peptides may be candidates for a peptide vaccine formulation effective against NTHi infections, even in otitis-prone children.
